Initiator Pharma Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los ingresos y los beneficios de Initiator Pharma disminuyan a un ritmo anual de 8.3% y 40% respectivamente. Se espera que el BPA disminuya en un 40.4% al año. Se prevé que la rentabilidad financiera sea de -6.2% en 3 años.

Información clave

-40.0%

Tasa de crecimiento de los beneficios

-40.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	45.7%
Tasa de crecimiento de los ingresos	-8.3%
Rentabilidad financiera futura	-6.2%
Cobertura de analistas	Low
Última actualización	28 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OM:INIT - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	52	-8	-9	-9	1
12/31/2025	N/A	-22	-23	-23	1
12/31/2024	138	37	35	35	1
6/30/2024	N/A	-12	-16	-16	N/A
3/31/2024	N/A	-18	-19	-19	N/A
12/31/2023	N/A	-23	-18	-18	N/A
9/30/2023	N/A	-27	-28	-28	N/A
6/30/2023	N/A	-29	-29	-29	N/A
3/31/2023	N/A	-33	-30	-30	N/A
12/31/2022	N/A	-38	-33	-33	N/A
9/30/2022	N/A	-40	-32	-32	N/A
6/30/2022	N/A	-43	-47	-47	N/A
3/31/2022	N/A	-34	-40	-40	N/A
12/31/2021	N/A	-21	-34	-34	N/A
9/30/2021	N/A	-16	-29	-29	N/A
6/30/2021	N/A	-10	-11	-11	N/A
3/31/2021	N/A	-8	-10	-10	N/A
12/31/2020	N/A	-9	-8	-8	N/A
9/30/2020	N/A	-10	-8	-8	N/A
6/30/2020	N/A	-9	-7	-7	N/A
3/31/2020	N/A	-9	-8	-8	N/A
12/31/2019	N/A	-8	-9	-9	N/A
9/30/2019	N/A	-7	-7	-7	N/A
6/30/2019	N/A	-9	-7	-7	N/A
3/31/2019	N/A	-8	-10	-10	N/A
12/31/2018	N/A	-10	-14	-14	N/A
9/30/2018	N/A	-13	-16	-16	N/A
6/30/2018	N/A	-11	-14	-14	N/A
3/31/2018	N/A	-10	N/A	-11	N/A
12/31/2017	N/A	-9	N/A	-8	N/A
9/30/2017	N/A	-7	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de INIT disminuyan en los próximos 3 años (-40% al año).

Beneficios vs. Mercado: Se prevé que INIT sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que INIT sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de INIT disminuyan en los próximos 3 años (-8.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de INIT disminuyan en los próximos 3 años (-8.3% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: INIT se prevé que no sea rentable en 3 años.

Initiator Pharma Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

Recent updates

New minor risk - Shareholder dilution

Now 20% undervalued

New major risk - Financial position

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento